DUBLIN, Ireland, Aug. 23, 2023 (GLOBE NEWSWIRE) — GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2023 and provided business updates. Second Quarter 2023 Financial Highlights Cash position Cash, cash equivalents…

Source

Previous articlePT434 – Kiyumí Retreats, Building Somatic Literacy, and Navigating Group Facilitation Challenges
Next articleSunstone Therapies in Collaboration with the University of Vermont Announces Publication of Study Showing Feasibility of Direct Observation of Therapeutic Connection in Psilocybin-Assisted Therapy